SCHEMBL3659873

SCHEMBL3659873

CC1CC(C(c2ccccc2)c2cccc(C(F)(F)F)c2)CCN1CC(=O)O

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 10/20 0.63
EPHX1 P07099 1/20 0.44
CACNA2D1 P54289 1/20 0.44
CACNA1B Q00975 1/20 0.44
CACNB1 Q02641 1/20 0.44
CACNA1C Q13936 1/20 0.44
KMT2A Q03164 1/20 0.42
TACR1 P25103 2/20 0.42
OPRM1 P35372 2/20 0.42
OPRD1 P41143 2/20 0.42
OPRK1 P41145 2/20 0.42
OPRL1 P41146 2/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM3 P20309 1/20 0.42
MRGPRX1 Q96LB2 1/20 0.42
SOS1 Q07889 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3663420 0.91 SLC6A9 (0.53) SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL3664802 0.87 SLC6A9 (0.56) SLC6A9
SCHEMBL3663874 0.83 SLC6A9 (0.53) SLC6A9EPHX1CACNA2D1CACNA1BCACNB1
SCHEMBL4135916 0.77 SLC6A9 (1.00) SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL4149045 0.77 SLC6A9 (1.00) SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL4145701 0.77 SLC6A9 (1.00) SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL4135920 0.77 SLC6A9 (1.00) SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL4139951 0.77 SLC6A9 (1.00) SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL4139944 0.77 SLC6A9 (1.00) SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL4135930 0.77 SLC6A9 (1.00) SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2231601-A2 GLYCINE TRANSPORTER-1 INHIBITORS Amgen, Inc (US) 2010-09-29 EP claimed
WO-2009075857-A2 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2009-06-18 WO claimed
US-8258306-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2012-09-04 US disclosed
US-20100298341-A1 Glycine Transporter-1 Inhibitors AMGEN INC. 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298341-A1 Glycine Transporter-1 Inhibitors SLC18A2, SLC7A11, SLC6A5 SLC6A9 8/4885EPHX1 1303/4885CACNA2D1 3216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.